1. Home
  2. ED vs NTRA Comparison

ED vs NTRA Comparison

Compare ED & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Consolidated Edison Inc.

ED

Consolidated Edison Inc.

HOLD

Current Price

$108.80

Market Cap

41.3B

Sector

Utilities

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$309.93

Market Cap

39.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ED
NTRA
Founded
1884
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.3B
39.1B
IPO Year
2009
2015

Fundamental Metrics

Financial Performance
Metric
ED
NTRA
Price
$108.80
$309.93
Analyst Decision
Hold
Strong Buy
Analyst Count
13
15
Target Price
$107.00
$259.07
AVG Volume (30 Days)
1.6M
1.2M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
3.26%
N/A
EPS Growth
7.63
0.65
EPS
2.54
N/A
Revenue
$16,918,000,000.00
$210,939,000.00
Revenue This Year
$9.18
$18.08
Revenue Next Year
$4.49
$19.65
P/E Ratio
$42.67
N/A
Revenue Growth
10.89
N/A
52 Week Low
$94.96
$156.71
52 Week High
$116.23
$326.03

Technical Indicators

Market Signals
Indicator
ED
NTRA
Relative Strength Index (RSI) 48.76 65.13
Support Level $104.38 $186.96
Resistance Level $109.33 N/A
Average True Range (ATR) 2.10 11.49
MACD -0.18 3.54
Stochastic Oscillator 36.69 78.64

Price Performance

Historical Comparison
ED
NTRA

About ED Consolidated Edison Inc.

Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York, including New York City, and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: